Matrix Metalloproteinases (MMPs) in patients with pulmonary tuberculosis (PT) and comorbid COPD Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Relationship between the Matrix Metalloproteinases (MMPs) levels and lung mechanic parameters established by impulse oscillometry (IOS) in patients with pulmonary tuberculosis (TB) Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs) and transforming growth factor-β (TGFβ) expression in small airways (SA) of usual idiopathic pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hip Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
System of matrix metalloproteinases in infiltrative pulmonary tuberculosis (with and without lung tissue destruction) Source: International Congress 2015 – Biomarkers in TB: immunology and physiology Year: 2015
Genes of detoxication system, matrix metalloproteinase 9 (MMP9) and set of group factors of blood in the risk of development of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 63s Year: 2004
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Correlation between matrix metalloproteinase-9 serum levels and disease severity in pulmonary tuberculosis patients Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of metalloproteinase-1(TIMP-1) as non-invasive biomarkers of remodelling in asthma Source: International Congress 2015 – Phenotyping asthma with biomarkers Year: 2015
Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor (TGFβ) in pleural tuberculosis Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Prognostic role of matrix metalloproteinase system / inhibitors in assessing the nature of reparative changes in infiltrative pulmonary tuberculosis (ITL). Source: International Congress 2018 – Triggers of acute lung injury: mechanical ventilation and oxygen levels Year: 2018
Matrix metalloproteinase (MMP) 9 is associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Matrix metalloproteinase (MMP) 12 is not associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Exocytosis of matrix metalloproteinases (MMPs) by pulmonary and systemic polymorphonuclear neutrophils (PMN) in hospital acquired pneumonia (HAP) Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
Expression of matrix metalloproteinases (MMPs) in primary spontaneous pneumothorax: MMP-9 as a potential biomarker for surgical intervention Source: International Congress 2017 – Thoracic surgery Year: 2017
Blood levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix matalloproteinases (TIMPs) as biomarkers of COPD. Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010